MY177001A - Phenothiazine compounds for treating mild cognitive impairment - Google Patents
Phenothiazine compounds for treating mild cognitive impairmentInfo
- Publication number
- MY177001A MY177001A MYPI20095255A MYPI20095255A MY177001A MY 177001 A MY177001 A MY 177001A MY PI20095255 A MYPI20095255 A MY PI20095255A MY PI20095255 A MYPI20095255 A MY PI20095255A MY 177001 A MY177001 A MY 177001A
- Authority
- MY
- Malaysia
- Prior art keywords
- cognitive impairment
- mild cognitive
- treating mild
- phenothiazine compounds
- phenothiazine
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 title abstract 3
- 208000027061 mild cognitive impairment Diseases 0.000 title abstract 3
- 125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 title 1
- KPYHKEZPEDJERZ-UHFFFAOYSA-N 10h-phenothiazine-1,2-diamine Chemical class C1=CC=C2NC3=C(N)C(N)=CC=C3SC2=C1 KPYHKEZPEDJERZ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94500607P | 2007-06-19 | 2007-06-19 | |
| PCT/GB2008/002066 WO2008155533A2 (en) | 2007-06-19 | 2008-06-17 | Phenothiazine compounds for treating mild cognitive impairment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY177001A true MY177001A (en) | 2020-09-01 |
Family
ID=39943003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20095255A MY177001A (en) | 2007-06-19 | 2008-06-17 | Phenothiazine compounds for treating mild cognitive impairment |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9211294B2 (enExample) |
| EP (1) | EP2167095B1 (enExample) |
| JP (1) | JP5725605B2 (enExample) |
| CN (1) | CN101820884B (enExample) |
| AU (1) | AU2008265045B2 (enExample) |
| BR (1) | BRPI0813670A2 (enExample) |
| CA (1) | CA2690746C (enExample) |
| DK (1) | DK2167095T3 (enExample) |
| ES (1) | ES2739546T3 (enExample) |
| HR (1) | HRP20191513T1 (enExample) |
| HU (1) | HUE045460T2 (enExample) |
| MY (1) | MY177001A (enExample) |
| PL (1) | PL2167095T3 (enExample) |
| PT (1) | PT2167095T (enExample) |
| SI (1) | SI2167095T1 (enExample) |
| WO (1) | WO2008155533A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602007008550D1 (de) | 2006-03-29 | 2010-09-30 | Wista Lab Ltd | 3,7-diamino-10h-phenothiazinsalze und ihre verwendung |
| SI2954932T1 (sl) * | 2007-10-03 | 2019-01-31 | Wista Laboratories Ltd. | Terapevtska uporaba diaminofenotiazinov |
| SG185094A1 (en) | 2010-04-30 | 2012-12-28 | Prostetta Antiviral Inc | Antiviral compounds |
| SI2673266T1 (sl) * | 2011-02-11 | 2016-11-30 | Wista Laboratories Ltd. | Fenotiazin diaminijeve soli in njihova uporaba |
| WO2012145567A1 (en) | 2011-04-20 | 2012-10-26 | Prosetta Antiviral Inc. | Antiviral compounds |
| EP3686181B1 (en) * | 2013-01-30 | 2024-07-17 | Ecolab USA Inc. | Hydrogen sulfide scavengers |
| US10304006B2 (en) * | 2013-02-15 | 2019-05-28 | The Charles Stark Draper Laboratory, Inc. | Method for integrating and fusing heterogeneous data types to perform predictive analysis |
| AU2016220096B2 (en) | 2015-02-17 | 2020-01-30 | Arizona Board Of Regents On Behalf Of Arizona State University | Phenothiazine analogues as mitochondrial therapeutic agents |
| SI4335517T1 (sl) * | 2016-07-25 | 2025-11-28 | Taurx Therapeutics Management Ltd. | Dajanje in odmerek diaminofenotiazinov |
| GB201614834D0 (en) * | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| EP4385512B1 (en) * | 2018-07-26 | 2025-12-03 | TauRx Therapeutics Management Ltd. | Optimised dosage of diaminophenothiazines in populations |
| MY209608A (en) * | 2019-04-10 | 2025-07-24 | Genting Taurx Diagnostic Centre Sdn Bhd | Adaptive neurological testing method |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| CA3257856A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT) |
| KR20250154422A (ko) | 2023-03-03 | 2025-10-28 | 타우알엑스 쎄라퓨틱스 매니지먼트 리미티드 | 미세혈관 뇌질환 치료를 위한 디아미노페노티아진 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0017060D0 (en) * | 2000-07-11 | 2000-08-30 | Hunter Fleming Ltd | Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| EP1617844A4 (en) * | 2003-04-03 | 2009-07-22 | Prana Biotechnology Ltd | TREATMENT OF NEUROLOGICAL DISEASES |
| WO2006032879A2 (en) * | 2004-09-23 | 2006-03-30 | Wista Laboratories Ltd. | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
| CN101084204B (zh) * | 2004-09-23 | 2012-12-05 | 卫思道制药有限公司 | 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法 |
| WO2006091728A2 (en) * | 2005-02-24 | 2006-08-31 | The Trustees Of The University Of Pennsylvania | Microtubule stabilizing compounds and methods of their use |
| EP2001556B1 (en) * | 2006-03-29 | 2014-10-01 | Wista Laboratories Ltd. | Thioninium compounds and their use |
| DE602007008550D1 (de) | 2006-03-29 | 2010-09-30 | Wista Lab Ltd | 3,7-diamino-10h-phenothiazinsalze und ihre verwendung |
| WO2007110629A1 (en) | 2006-03-29 | 2007-10-04 | Wista Laboratories Ltd | Inhibitors of protein aggregation |
| SI2457905T1 (sl) | 2006-07-11 | 2016-12-30 | Wista Laboratories Ltd. | Postopki sinteze in/ali čiščenja diaminofenotiazinijevih spojin |
-
2008
- 2008-06-17 DK DK08762390.6T patent/DK2167095T3/da active
- 2008-06-17 BR BRPI0813670-0A2A patent/BRPI0813670A2/pt not_active Application Discontinuation
- 2008-06-17 US US12/665,608 patent/US9211294B2/en active Active
- 2008-06-17 ES ES08762390T patent/ES2739546T3/es active Active
- 2008-06-17 JP JP2010512761A patent/JP5725605B2/ja active Active
- 2008-06-17 HU HUE08762390A patent/HUE045460T2/hu unknown
- 2008-06-17 PT PT08762390T patent/PT2167095T/pt unknown
- 2008-06-17 WO PCT/GB2008/002066 patent/WO2008155533A2/en not_active Ceased
- 2008-06-17 PL PL08762390T patent/PL2167095T3/pl unknown
- 2008-06-17 CN CN2008801031955A patent/CN101820884B/zh active Active
- 2008-06-17 SI SI200832080T patent/SI2167095T1/sl unknown
- 2008-06-17 AU AU2008265045A patent/AU2008265045B2/en active Active
- 2008-06-17 CA CA2690746A patent/CA2690746C/en active Active
- 2008-06-17 MY MYPI20095255A patent/MY177001A/en unknown
- 2008-06-17 EP EP08762390.6A patent/EP2167095B1/en active Active
- 2008-06-17 HR HRP20191513 patent/HRP20191513T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008265045B2 (en) | 2014-02-27 |
| BRPI0813670A2 (pt) | 2014-12-30 |
| JP5725605B2 (ja) | 2015-05-27 |
| HUE045460T2 (hu) | 2019-12-30 |
| HRP20191513T1 (hr) | 2019-11-29 |
| US20100184752A1 (en) | 2010-07-22 |
| ES2739546T3 (es) | 2020-01-31 |
| CN101820884B (zh) | 2013-08-28 |
| EP2167095B1 (en) | 2019-05-29 |
| AU2008265045A1 (en) | 2008-12-24 |
| DK2167095T3 (da) | 2019-07-29 |
| CA2690746C (en) | 2018-01-02 |
| SI2167095T1 (sl) | 2019-09-30 |
| US9211294B2 (en) | 2015-12-15 |
| CA2690746A1 (en) | 2008-12-24 |
| WO2008155533A3 (en) | 2009-02-19 |
| PT2167095T (pt) | 2019-08-06 |
| PL2167095T3 (pl) | 2019-11-29 |
| WO2008155533A2 (en) | 2008-12-24 |
| CN101820884A (zh) | 2010-09-01 |
| JP2010530403A (ja) | 2010-09-09 |
| EP2167095A2 (en) | 2010-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY177001A (en) | Phenothiazine compounds for treating mild cognitive impairment | |
| NL301145I1 (enExample) | ||
| MX2009006466A (es) | Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina. | |
| IL233634A0 (en) | Methods, compositions and kits for treating medical conditions | |
| MX2011012015A (es) | Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer. | |
| MX2010004219A (es) | Agentes de enlace de cd19 y usos de los mismos. | |
| MX2009005725A (es) | Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13. | |
| MX2009006536A (es) | Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales. | |
| MX2022009759A (es) | El uso de 1-(4-ciano-3-trifluorometil-fenil)-3-[7-(4-ciano-3-trifl uorometil-fenil)-6-tioxo-5-p-tolilo-5,7-diazaespiro[3.4]oct-8-ili deno]-tiourea. | |
| TW200716624A (en) | Compounds for modulating TRPV3 function | |
| TNSN08400A1 (en) | Organic compounds and their uses | |
| MX2007016322A (es) | Composiciones y metodos para el diagnostico y tratamiento de tumor. | |
| MX360301B (es) | Moleculas pequeñas que contienen boro como agentes antiinflamatorios. | |
| HUE059861T2 (hu) | N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra | |
| MY158325A (en) | Multitype peptide compositions and methods for treatment or prevention of human papillpmavirus infection | |
| WO2010036395A3 (en) | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds | |
| EP1924293A4 (en) | COMPOSITION AND METHOD FOR THE PREVENTION AND TREATMENT OF DIABETES TYPE I | |
| ZA201002764B (en) | Benzodiazepinone compounds useful in the treatment of skin conditions | |
| BRPI0908635A8 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
| MX2010002909A (es) | Metodo de tratamiento de pacientes de hepatitis c. | |
| MX2009011346A (es) | Tapentadol para tratamiento de dolor con artritis. | |
| MY155340A (en) | Use of cathepsin c | |
| TW200716088A (en) | Formulations and methods for treating amyloidosis | |
| TW200716015A (en) | Methods and apparatuses for sealing ophthalmic lens packages | |
| IN2012DN02470A (enExample) |